Key facts
- It has raised $82.6M; the latest was Grant ($2.6M) in Jan 2025.
- Notable investors include European Commission, European Union, Novo Holdings, Johnson & Johnson JJDC, Industrifonden — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Asgard Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Asgard Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Asgard Therapeutics
Operator of a pioneering private biotech company intended for in vivo direct cell reprogramming for cancer immunotherapy. The company builds reprogramming technologies to develop gene therapy products to set efficient and personalized immune responses in motion, enabling patients to acquire new forms of treatment for cancer resistant to conventional treatment methods.
- Sector
- Healthcare
- HQ
- Lund, Sweden
- Founded
- 2018
- Employees
- 27
- Website
- asgardthx.com/
- Ownership
- Privately Held (backing)
Asgard Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Asgard Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Asgard Therapeutics in its N-PORT filings yet. We sweep new filings monthly.